Aminosalicylates, thiopurines and methotrexate in inflammatory bowel disease: Is it possible to discontinue the treatment?
| Autor: | Lilian Flores Pérez, Patricio Ibáñez Lazo, Carolina Figueroa Corona, Rodrigo Quera Pino, Rocío Sedano Muñoz |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
Azathioprine Disease Inflammatory bowel disease 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Mesalazine Internal medicine Medicine Humans Significant risk Mesalamine business.industry Mercaptopurine Anti-Inflammatory Agents Non-Steroidal Remission Induction medicine.disease Inflammatory Bowel Diseases Ulcerative colitis Methotrexate chemistry Withholding Treatment 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology business Immunosuppressive Agents medicine.drug |
| Zdroj: | Gastroenterologia y hepatologia. 42(5) |
| ISSN: | 0210-5705 |
| Popis: | The current goals of treatment in inflammatory bowel disease, both Crohn's disease and ulcerative colitis, are to achieve clinical, endoscopic and ideally histological remission and improve the quality of life of these patients. Current therapies are effective in achieving remission in most cases, but there is a lack of clear guidelines on their optimal duration. This review aims to evaluate the current evidence on the withdrawal of therapy with 5-aminosalicylates, thiopurines and methotrexate. We also aim to identify which specific group of patients, while in remission and in the absence of risk factors, may be able to discontinue therapy without a significant risk of relapse. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|